tw0122
1 월 전
Warrants at $1 ... Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented, “The proceeds from the financings we have completed since the start of this year have greatly strengthened our balance sheet and are estimated to have provided the necessary funding to advance the development of our lead program into the middle of the first quarter of 2025. With these proceeds in hand and the continued progress toward interim and topline data for our lead program, expected in the coming quarters, we believe we are well positioned to realize the full potential of GRI-0621 to provide significant benefit to IPF patients.”
zj3001
2 월 전
Additional data added here…
$GRI is very transparent on their goal here. Just read between the lines, Pharma partner or Buyout incoming!
✅Company stated earlier this year that it will have a partner or implied buyout when positive Phase2 verified proof of concept.
b2idigital.com/gri-bio
✅ News last week stating positive phase 2 data has been demonstrated, study on going.
gribio.com/gri-bio-presen…
✅ Phase 2 expected to be done this year (2024).
clinicaltrials.gov/study/NCT06331…
✅ 10-Q 8/14/24, Page 9, “Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.”
s3.amazonaws.com/sec.irpass.cc/…
✅Nasdaq compliance due by March 2025.
✅Executives have a track record of building pharma drugs/companies and selling them off. Their profiles discuss deal markers, IP protection, acquisition/mergers.
✅2.93m shares OS
✅ GRI Bio’s key executives own the following amounts of shares:
Walter Marc Hertz, CEO, holds approximately 385,510 shares.
Albert Agro, Chief Medical Officer, owns around 172,189 shares.
Vipin Chaturvedi, Chief Scientific Officer, also owns 172,189 shares.
Leanne Kelly, Chief Financial Officer, holds 83,333 shares.
Grok has this info for insiders
Based on the latest available data up to October 19, 2024, GRI Bio, Inc. (GRI) is largely owned by insiders,
- **Joseph E. Payne** owns **29.42%** of the company, making him the largest individual shareholder with 861,250 shares.
- **Arcturus Therapeutics Holdings Inc** holds **28.82%**.
- **Walter Marc Hertz** has **13.17%**.
- **Ofir Levi** owns **6.72%**.
- **Albert Agro** and **Vipin Chaturvedi** each own **5.88%**.
- **Richard Ammer** and **Pharma Gmbh Salmon** each hold **1.61%**.
zj3001
2 월 전
Things to note that I posted on X and ST.
✅Company stated earlier this year that it will have a partner or implied buyout when positive Phase2 verified proof of concept.
✅ News last week stating positive phase 2 data has been demonstrated, study on going.
https://gribio.com/gri-bio-presents-positive-preclinical-data-demonstrating-gri-0621s-ability-to-inhibit-invariant-natural-killer-t-inkt-cell-activity-and-reduce-important-inflammatory-and-fibrotic-drivers-in-idiopa/
✅ Phase 2 expected to be done this year (2024).
https://clinicaltrials.gov/study/NCT06331624?spons=GRI%20Bio%20Operations,%20Inc.&rank=1
✅ 10-Q 8/14/24, Page 9, “Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.”
https://s3.amazonaws.com/sec.irpass.cc/2647/0001824293-24-000105.htm
✅Nasdaq compliance due by March 2025.
Hot Features
프리미엄
실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
glenn1919
6 일 전
TheFinalCD
2 월 전
